Sanofi India announced the Supreme Court dismissed its petition to quash criminal proceedings initiated by the CBI. The case involves alleged procurement irregularities at BARC between 2012 and 2015. While the company confirmed no penalties or operational restrictions are imposed, the legal process will now proceed to trial.
Sanofi India Faces Continued Legal Trial After Supreme Court Ruling
Supreme Court dismisses petition to quash CBI criminal proceedings; case remains pending for trial.
Company confirms no current financial penalties or operational restrictions following the judicial order.
Reader Takeaway: The court ruling keeps the trial alive but does not establish any finding of company guilt.
What just happened
Sanofi India Limited received an order from the Supreme Court of India dated September 7, 2026, which dismissed the company’s petition to quash ongoing criminal proceedings initiated by the Central Bureau of Investigation (CBI). The ruling specifically addresses the maintainability of prosecuting the corporate entity even in instances where no individual employee has been formally arraigned as an accused party.
Why this matters
The litigation stems from a criminal complaint regarding pharmaceutical supplies provided to the Bhabha Atomic Research Centre (BARC), Mysore, between 2012 and 2015. The CBI’s allegations center on a reported conspiracy involving a BARC official to influence procurement decisions. For investors, the continuation of the trial process represents a prolonged period of legal uncertainty surrounding these legacy issues.
The backstory
The company had sought to have these criminal proceedings quashed through the Supreme Court. The court’s recent decision ensures the legal process will continue, though the court clarified that this specific order does not touch upon the merits of the case or assign any finding of guilt to Sanofi India.
What changes now
Management is currently reviewing the Supreme Court judgment to determine its future litigation strategy. The company emphasized that the order carries no immediate financial impact, such as fines or penalties, nor does it place any restrictions on day-to-day business operations.
What to track next
Shareholders should monitor the progression of the criminal trial in the lower courts. Future developments regarding the merits of the CBI allegations and the company’s legal defense strategy remain the primary focus areas for market participants.